For individuals facing Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a serious condition, the introduction of this treatment and the formulated version represents a significant change. These groundbreaking therapies preserve the transthyretin protein, halting its harmful build-up and reducing the severity of the condition . Patients are now exper